Table 3.
Adjusted change in RDQ score for the GERD dimension and the individual RDQ dimensions from baseline to the end of treatment (ITT population)
| RDQ dimension | LSM change (95% CI) | LSM differencea | |
|---|---|---|---|
| Gaviscon DA (n = 536) | Placebo (n = 537) | (95% CI); P‐valueb | |
| GERD (heartburn + regurgitation) | −1.27 (−1.37 to −1.16) | −1.06 (−1.17 to −0.95) | −0.21 (−0.31 to −0.11); P < 0.0001 |
| Heartburn | −1.16 (−1.28 to −1.04) | −0.95 (−1.07 to −0.83) | −0.21 (−0.32 to −0.10); P = 0.0001 |
| Regurgitation | −1.37 (−1.48 to −1.26) | −1.16 (−1.27 to −1.05) | −0.21 (−0.32 to −0.09); P = 0.0004 |
| Dyspepsia | −0.98 (−1.10 to −0.86) | −0.80 (−0.91 to −0.68) | −0.18 (−0.29 to −0.08); P = 0.0004 |
CI, confidence interval; GERD, gastroesophageal reflux disease; LSM, least‐squares mean; RDQ, reflux disease questionnaire; DA, Double Action; ITT, intent‐to‐treat.
a
LSM difference is the difference in RDQ score changes between treatment groups (LSM change for Gaviscon DA group minus LSM change for placebo group).
b
P‐value for comparison between treatment groups.